Anticancer Biosciences utilizes synthetic lethality to develop targeted cancer therapies that selectively induce cancer cell death while preserving healthy cells. By leveraging proprietary chemical and natural product libraries, the company aims to create safer and more effective treatment options for patients facing various cancer types.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies damage healthy cells alongside cancerous ones, leading to severe side effects and limiting treatment effectiveness. Traditional approaches often fail to selectively target cancer cells, resulting in a narrow therapeutic window.
Solution
Anticancer Biosciences leverages synthetic lethality to develop targeted cancer therapies that selectively induce cancer cell death while preserving healthy cells. The company utilizes proprietary chemical and natural product libraries and discovery platforms in cancer biology to identify novel mechanisms that trigger cancer cell death without harming healthy cells. This approach aims to create safer and more effective precision cancer therapies with fewer off-target effects. By exploiting synthetic lethal interactions, Anticancer Biosciences seeks to develop treatments that specifically target vulnerabilities unique to cancer cells.
Target Audience
The primary target audience includes patients facing various cancer types and the oncologists seeking more effective and less toxic treatment options.
Features
- Exploits synthetic lethality principles to selectively target cancer cells.
- Employs proprietary chemical and natural product libraries for drug discovery.
- Utilizes innovative high-throughput screening approaches to identify novel drug targets.
- Focuses on developing therapies that induce cancer cell death without harming healthy cells.